Ventyx Biosciences appoints Mark McKenna as strategic advisor

Ventyx Biosciences (VTYX) announced that the Company added two experts to their advisory board and provided an update to its ongoing Phase 2 study of VTX2735 in patients with recurrent pericarditis. Mark McKenna, Strategic Advisor. McKenna is the founder, Chairman and CEO of Mirador Therapeutics. Peter Libby, Clinical Advisor. Dr. Libby is a cardiovascular specialist at Mass General Brigham Heart & Vascular Institute and immediate past president of the International Atherosclerosis Society. “We are fortunate to attract such an outstanding group of scientists, clinicians and strategic advisors to work with us. Mr. McKenna and Dr. Libby’s expertise will be invaluable as we continue to evaluate clinical and strategic options for our oral NLRP3 portfolio,” said Raju Mohan, PhD, CEO. “They will advise us on key decisions with respect to VTX3232, our CNS-penetrant NLRP3 inhibitor, that generated two positive Phase 2 data sets earlier this year, and VTX2735, our peripherally restricted NLRP3 inhibitor, that is in an ongoing Phase 2 study in patients with recurrent pericarditis.”